[ad_1]
A Moderna vaccine (COVID-19) is seen at the LA Mission homeless shelter on Skid Row in Los Angeles, California, United States, February 10, 2021.
Lucy Nicholson | Reuters
Moderna said Thursday that he expects to generate sales of $ 18.4 billion from his Covid-19 vaccine this year.
Releasing its fourth quarter results, Moderna also announced that its medical director, Tal Zaks, will be leaving the company at the end of September. The company said it had retained Russell Reynolds “to recruit a new CMO with global and commercial experience.”
Moderna shares rose 3.9% in pre-market operations.
The news comes a day after the company announced that it planned to produce at least 700 million doses of the Covid vaccine this year. He also said he plans to produce up to 1.4 billion doses of the Covid vaccine in 2022.
Pfizer, which also has a vaccine licensed in the United States, said earlier this month that it plans to sell around $ 15 billion in doses this year.
Moderna has reached an agreement with the federal government for 300 million doses and has shipped approximately 55 million doses to the U.S. It plans to complete delivery of the first 100 million doses to the U.S. by the end of the year. first quarter, the second of 100 million doses by the end of May and August 3.
Moderna, like other vaccine makers, is working quickly to meet demand for vaccines that will hopefully help end the pandemic, which has infected more than 112 million people and killed at least 2.4 million , according to data compiled by Johns Hopkins University.
The company is in talks with the Food and Drug Administration over a proposal to fill its Covid vaccine vials with up to five additional doses to ease a manufacturing bottleneck. A two-dose vial of Moderna vaccine contains 10 doses, enough to inoculate five people, according to the Centers for Disease Control and Prevention.
The company also said Thursday that it was in talks with the World Health Organization-backed COVAX initiative to deliver doses this year and into 2022.
Moderna’s vaccine has been cleared by the FDA for use in people 18 years of age and older. Clinical trial studies are incomplete for children, whose immune systems may respond differently from adults.
The company said Thursday it has completed recruiting 3,000 participants in a clinical trial testing its vaccine in children aged 12 to 17.
[ad_2]
Source link